AbbVie (ABBV) Tops Q4 EPS by 10c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Abbvie (ABBV) PT Raised to $212 at Goldman Sachs
February 3, 2025 5:17 AM ESTGoldman Sachs analyst Chris Shibutani raised the price target on Abbvie (NYSE: ABBV) to $212.00 (from $208.00) while maintaining a Buy rating.
The analyst comments "Relative outperformance from ABBV shares (+4.7% on Friday vs. XLV -0.3%) was earned in our view, with continued strong momentum from Skyrizi and Rinvoq enabling the delivery of... More
